CAR T-cells in CLL: the current landscape

CAR T-cells in CLL: the current landscape

VJHemOnc

1 year
315 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, gives an overview of the current data, explaining how CAR T-cell therapy appears to be less effective in CLL than in other diseases. He discusses how their potency in this disease might be improved, potentially via the addition of ibrutinib, and highlights three upcoming clinical trials in the field, which might be the turning point for this therapy in CLL.
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
1 Views
Cancer-News 6 hours
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
24 Views
Cancer-News 1 day
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 1 day
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 1 day
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 1 day
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 2 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 2 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 2 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
9 Views
kidneycancer 3 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 3 days